Immunocore Holdings (IMCR) Long-Term Investments (2019 - 2022)

Immunocore Holdings (IMCR) has reported Long-Term Investments for 4 consecutive years, with $1.3 million the latest figure, recorded in Q4 2022.

• Quarterly Long-Term Investments fell 1.37% year-over-year to $1.3 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $1.3 million (down 1.37% YoY) and the FY2022 annual result came in at $1.3 million, down 3.37% from the prior year.
• Long-Term Investments retreated to $1.3 million in Q4 2022 per IMCR's latest filing, from $1.3 million in the prior quarter.
• Over the last five years, Long-Term Investments for IMCR reached as high as $180.0 million in Q4 2020 and fell as low as $1.3 million in Q4 2022.
• A 4-year average of $71.5 million and a median of $52.4 million in 2019 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments soared 73.8% — and 2021, when it sank 99.29%.
• Year by year, Long-Term Investments stood at $103.6 million in 2019, then surged by 73.8% to $180.0 million in 2020, then plunged by 99.29% to $1.3 million in 2021, then declined by 1.37% to $1.3 million in 2022.
• According to Business Quant data, Long-Term Investments over the past three periods registered $1.3 million, $1.3 million, and $180.0 million for Q4 2022, Q4 2021, and Q4 2020 respectively.